CeraVe Acne Control Cleanser: the label and the current page

The manufacturer describes Acne Control Cleanser as a gel-to-foam product for acne-prone oily skin. It identifies salicylic acid at 2%, while the corresponding label states acne treatment as the purpose and includes rinsing in its directions. That establishes a cleansing preparation rather than a leave-on cream or serum. Product page and L’Oreal label.

Renewing SA Cleanser, Acne Control Gel and the brand's benzoyl-peroxide washes are different products. Their neighboring descriptions cannot fill gaps in this record. The format comparison retains exact names so an ingredient claim does not drift from one listing to another.

The DailyMed printer-friendly record identifies L’Oreal USA Products Inc., NDC 49967-840, and a March 2025 revision. We accessed that posted version during this review. The date describes the record being read; it does not establish when a particular bottle was manufactured or which package a retailer will fulfill. Posted labeling.

The current website gives its own ingredient list and tells readers to consult their package for updated ingredients. For example, sodium cocoyl isethionate appears in the posted label's inactive list but not in the captured website list. Those observations support a version question, not a conclusion about a defective product. Website ingredient caveat.

The label classifies this product as an OTC monograph drug under M006. We report that category rather than describe the listing as an individually approved application or an FDA endorsement of the brand. A posted label is evidence of its stated identity and claims; it is not our independent audit of a manufacturer's compliance or clinical performance. Regulatory entry.

The compounded-versus-retail explanation places the category beside the different record for Pore Favor. That distinction is informative without turning prescription access or retail availability into a quality score. Approval status and personal suitability still require separate, precise statements.

FDA also cautions that assignment of an NDC number is not approval and that directory inclusion does not mean the agency verified the submitted information. The identifier helps locate a record; it is not a clinical seal. FDA directory explanation.

CeraVe promotes its ceramides, niacinamide and oil-absorbing clay, with claims concerning skin barrier support, acne and visible shine. Its page also uses non-comedogenic, allergy-tested and fragrance-related language. These are manufacturer descriptions; they do not establish that every user will find the cleanser comfortable. Manufacturer claims.

The label specifically warns about greater likelihood of dryness and irritation alongside another topical acne medicine. That warning is not canceled by supportive ingredients. AAD's moisturizer guidance provides broader context for irritation with acne treatments, without proving a remedy or a brand preference for an individual. Label warning and AAD context.

The public manufacturer page displays $17.99. Our capture does not unambiguously associate that figure with one selected package quantity. Meanwhile, the label includes several bottle sizes and a sample packet. Assigning the price to any one of those would add information the reviewed page has not established. Price page and package records.

For that reason, this review does not calculate unit value, a monthly expense or an expected replacement date. The annual-supply discussion concerns a different kind of offer but the same reading problem: a price needs its actual unit, and a sales unit is not a personal treatment duration.

The shared salicylic-acid percentage is a real field to compare, but it leaves the complete formulation, format and outcome evidence unresolved. The Ordinary solution review concerns a serum; the Pore Favor review concerns an advertised compounded cream. No conversion or substitution can be inferred from that matching number.

The two-percent article develops the distinction without ranking strength or giving a regimen. A genuine outcome comparison would need the exact preparations and the relevant study design. Ingredient overlap alone cannot establish how people would respond or which product would better address a clinically assessed concern.

The remaining documentation questions concern the supplied package, its full ingredient version and the current applicable directions. A manufacturer or pharmacist can help clarify a label question; a qualified clinician can assess a medical concern. Those roles should not be assumed to have been performed simply because a retail page is detailed.

Our version-and-label record guide helps retain the exact wording without diagnosing a reaction or assigning causation. This review's contribution is a clearer record of what is public and what is still unknown. It does not demonstrate comparative efficacy, promise gentleness or make a treatment recommendation from the cleanser's commercial description.

Several other cleanser records pose the same identity question in different ways. The La Roche-Posay Effaclar review follows a current page beside separately dated labels. The INKEY List cleanser review keeps a cleanser distinct from the neighboring serum and separates customer summaries from the brand’s trial account. The Cetaphil Pore Clearing cleanser review focuses on the exact named gel rather than a different cream. The Clearasil wash review examines how a fast-result headline relates to a posted wash record. Their purpose here is to make document comparison clearer, without treating similar cleansing formats as proof of equivalent performance.